CN Patent

CN107531667A — 1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形

Assigned to Pfizer Inc · Expires 2018-01-02 · 8y expired

What this patent protects

本发明涉及1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形，并涉及其药物组合物，涉及用于制备和分离这样的晶形和组合物的中间体和方法，并涉及在治疗哺乳动物(特别是人类)的异常细胞生长中使用这样的晶形和组合物的方法。

USPTO Abstract

本发明涉及1‑((2R,4R)‑2‑(1H‑苯并[d]咪唑‑2‑基)‑1‑甲基哌啶‑4‑基)‑3‑(4‑氰基苯基)脲马来酸盐的晶形，并涉及其药物组合物，涉及用于制备和分离这样的晶形和组合物的中间体和方法，并涉及在治疗哺乳动物(特别是人类)的异常细胞生长中使用这样的晶形和组合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN107531667A
Jurisdiction
CN
Classification
—
Expires
2018-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.